MetaCap

Replimune Group Inc. Company Profile

NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

19.07-0.16 (-0.83%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Replimune Group at a glance

Replimune Group Inc. (NASDAQ: REPL) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Woburn, MA. Replimune Group is led by Dr. Sushil Patel Ph.D. and employs about 465 people. The company's shares have traded publicly since 2018.

At a market capitalization of $1.82 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001737953, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Replimune Group do?

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Replimune Group Inc.
Ticker
NASDAQ: REPL
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Sushil Patel Ph.D.
Employees
465
Headquarters
500 Unicorn Park Drive, Woburn, MA, United States
Phone
781 222 9600
IPO year
2018
SEC CIK
0001737953
Latest annual report
10-K · Jun 29, 2026

Companies similar to Replimune Group

REPL peer companies
CompanyPrice% ChgMarket capCompare
COAGHemab Therapeutics Holdings Inc.39.29-1.43%$1.84Bvs REPL
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs REPL
LYCALycia Therapeutics Inc.33.07+4.09%$1.72Bvs REPL
MAZEMaze Therapeutics Inc.31.37-3.27%$1.72Bvs REPL
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs REPL
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs REPL
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs REPL
ALVOAlvotech4.12-3.96%$1.47Bvs REPL

Related